January 2026
1. WAN M, Yi C, Wang Y, Qiu Y, et al
   A comparative analysis of left ventricular myocardial work in patients with diabetic and non?diabetic kidney disease after peritoneal dialysis.
   Am J Nephrol. 2026 Jan 15:1-19. doi: 10.1159/000550324.
   

   >> Share

   
   
2. AN Y, Zhang H
   SGLT-2 Inhibitors: A Deeper Dive into Their Renal Protective Properties beyond Glycemic Control and Proteinuria Reduction.
   Am J Nephrol. 2026;57:53-65.
   

   >> Share

   
   November 2025
3. MC CAUSLAND FR, Claggett BL, Jarolim P, McGrath MM, et al
   Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia.
   Am J Nephrol. 2025 Nov 3:1-19. doi: 10.1159/000549255.
   

   >> Share

   
   September 2025
4. FERNANDEZ-FERNANDEZ B, Hasegawa T, Saruta Y, Li Guan Y, et al
   Plasma IL-22 predicts progression of early diabetic kidney disease.
   Am J Nephrol. 2025 Sep 8:1-21. doi: 10.1159/000547738.
   

   >> Share

   
   June 2025
5. LV L, Zheng W, Hu M, Cheing GLY, et al
   The role of cell-cell communication in renal damage and the therapeutic targeting of diabetic kidney disease.
   Am J Nephrol. 2025 Jun 13:1-22. doi: 10.1159/000546739.
   

   >> Share

   
   January 2025
6. KITAMURA H, Tanaka S, Hiyamuta H, Tsuruya K, et al
   Associations of Causes of Chronic Kidney Disease with Disease Progression and Mortality: Insights from the Fukuoka Kidney disease Registry (FKR) Study.
   Am J Nephrol. 2025 Jan 8:1-21. doi: 10.1159/000543201.
   

   >> Share

   
   
7. MCDONNELL T, Kalra PA, Vuilleumier N, Cockwell P, et al
   The Impact of Primary Renal Diagnosis on Prognosis and the Varying Predictive Power of Albuminuria in the NURTuRE-CKD Study.
   Am J Nephrol. 2025;56:1-12.
   

   >> Share

   
   November 2024
8. FERREIRA JP, Oliveira AC, Vasques-Novoa F, Leite AR, et al
   Mineralocorticoid receptor antagonist combined with a SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: a meta-analysis of randomized trials.
   Am J Nephrol. 2024 Nov 7:1-13. doi: 10.1159/000541686.
   

   >> Share

   
   October 2024
9. SHIAO CC, Chiu CW, Chang YM, Liu MC, et al
   Comprehensive Evaluation of the Cardiovascular Protective Effects of SGLT2 Inhibitors in Patients with Advanced Chronic Kidney Disease: A Real-World Evidence.
   Am J Nephrol. 2024 Oct 21:1-28. doi: 10.1159/000542132.
   

   >> Share

   
   May 2024
10. MOLONEY BM, Chertow GM, Mc Causland FR
    Association of Diabetes with Changes in Blood Pressure during Hemodialysis: A Secondary Analysis of the Frequent Hemodialysis Network Daily Trial.
    Am J Nephrol. 2024 May 23. doi: 10.1159/000539451.
    

    >> Share

    
    February 2024
11. STAVAS J, Silva AL, Wooldridge TD, Aqeel A, et al
    Rilparencel (Renal Autologous Cell Therapy-REACT(R)) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers.
    Am J Nephrol. 2024 Feb 29. doi: 10.1159/000537942.
    

    >> Share

    
    
12. MAKAWI AT, Tawfik YMK, Dixon DL, McMahon GM, et al
    Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease.
    Am J Nephrol. 2024 Feb 28:1-4. doi: 10.1159/000536540.
    

    >> Share

    
    
13. CROUCH E, Yell N, Herbert L, Browne T, et al
    Availability and quality of dialysis care in rural versus urban U.S. counties.
    Am J Nephrol. 2024 Feb 11. doi: 10.1159/000537763.
    

    >> Share

    
    January 2024
14. TUTTLE KR, Rossing P, Hauske SJ, Cronin L, et al
    Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease.
    Am J Nephrol. 2024;55:262-272.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share